Eli Lilly Acquires Rights to Non-Opioid Pain Treatment

Company hopes to replace recently failed candidates.

Eli Lilly is looking to bring new assets into its pipeline. In February 2019, it acquired Loxo Oncology, Inc for $8 billion to expand its oncology position with a pipeline of highly selective potential medicines for patients with genomically defined cancers.

It recently followed that purchase with the acquisition of rights to Centrexion’s early-stage non-opioid pain drug CNTX-0290 for $47.5 million up front. CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist that Centrexion acquired from Boehringer Ingelheim in 2016. Centrexion could receive up to an additional $575 million in potential development and regulatory milestones, as well as an additional $375 million in potential sales milestones and tiered royalties if the drug is approved.


Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.